--- title: "Zenagamtide | PepTracker Pro" url: https://peptrackerpro.com/peptides/zenagamtide description: "A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Zenagamtide Low Evidence A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026. Aliases NN9487 +1 more Evidence Low Evidence Last Updated 2026-06-05 Reading Time 3 min ## What It Is Zenagamtide (NN9487) is an investigational once-weekly unimolecular co-agonist of the GLP-1 receptor and amylin receptor, developed by Novo Nordisk. It is distinct from CagriSema — rather than combining two separately developed molecules, zenagamtide is a single engineered peptide designed to activate both GLP-1 and amylin receptor pathways simultaneously, potentially offering improved pharmacokinetic and tolerability properties compared to a fixed-dose combination. GLP-1 receptor activation reduces appetite and slows gastric emptying, while amylin receptor activation in the hypothalamus and hindbrain produces complementary satiety signaling through a separate neural circuit — the same dual-pathway rationale behind CagriSema, now encoded in one molecule. Phase 2 clinical data presented at the ADA 2026 Scientific Sessions (June 5–8, New Orleans) showed that subcutaneous zenagamtide achieved up to 24.3% weight loss in obesity trials and 14.5% weight loss with 1.8% HbA1c reduction in a type 2 diabetes Phase 2 trial at 36 weeks. The oral formulation demonstrated 7.6% placebo-adjusted weight loss in T2D and approximately 13% in obesity Phase 2 data. Both formulations remained on an ascending trajectory without plateau at study end. In early 2026, Novo Nordisk initiated the Phase 3 AMAZE program: AMAZE 1 (obesity, 84 weeks vs placebo) and AMAZE 2 (T2D + obesity, 84 weeks vs placebo), with additional Phase 3 trials planned for obstructive sleep apnea and knee osteoarthritis in H2 2026. Zenagamtide represents Novo Nordisk's next-generation amylin-GLP-1 asset — a conceptually cleaner successor to the CagriSema combination — and, if Phase 3 data confirm the Phase 2 signal, could become the cornerstone of Novo Nordisk's post-Wegovy pipeline. Also known as: NN9487, Amycretin (injectable form) ## Regulatory Status Investigational — Phase 3 (AMAZE program) Phase 3 AMAZE 1 (obesity) and AMAZE 2 (T2D + obesity) initiated in early 2026, 84-week trials. Phase 3 for T2D planned H2 2026. Phase 2 data presented at ADA 2026 Scientific Sessions (June 5–8). Not yet filed with any regulatory agency. Effective: Early 2026 View FDA Source (https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html) ## Why Researchers Study It Zenagamtide is studied as a single-molecule GLP-1/amylin co-agonist — a mechanistic refinement on the dual-pathway obesity thesis demonstrated by CagriSema. Its unimolecular design may simplify dosing, improve pharmacokinetics, and reduce combinatorial complexity compared to fixed-dose combinations, while targeting the same two satiety hormone pathways that have produced the highest weight loss in clinical development. ## Proposed Mechanisms - Activates GLP-1 receptors to reduce appetite and slow gastric emptying - Activates amylin receptors (area postrema, hypothalamus) via a distinct satiety neuronal circuit - Dual-pathway satiety signaling from a single unimolecular agent - Available in both subcutaneous injectable and oral formulations - Long-acting once-weekly pharmacokinetics designed for stable receptor engagement ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 (Obesity, subcutaneous) | Adults with obesity — once-weekly subcutaneous zenagamtide | Up to 24.3% weight loss; no plateau at study end | Source: https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html | | Phase 2 (T2D, subcutaneous) | Adults with type 2 diabetes — subcutaneous zenagamtide, 36 weeks | 14.5% weight loss; 1.8% HbA1c reduction; 89% of participants reached HbA1c <7% | Source: https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html | | Phase 2 (T2D, oral) | Adults with type 2 diabetes — oral zenagamtide formulation | 7.6% placebo-adjusted weight loss; 78% of participants reached HbA1c <7%; no plateau | Source: https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html | | Phase 2 (Obesity, oral) | Adults with obesity — oral zenagamtide formulation | ~13% weight loss; ascending trajectory without plateau | Source: https://remypeptides.com/research/zenagamtide-amycretin-glp1-amylin | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Researching Zenagamtide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=zenagamtide) ## Safety & Cautions - Phase 3 trials initiated but no pivotal results available yet - Long-term safety profile not established beyond 36-week Phase 2 data - Not filed or approved by any regulatory agency - Oral formulation efficacy (~13%) below subcutaneous (~24.3%) — typical of oral GLP-1 class - Head-to-head comparisons with CagriSema, tirzepatide, and retatrutide not yet available ## Comparisons See how Zenagamtide compares to related peptides: Zenagamtide vs Amycretin: https://peptrackerpro.com/compare/zenagamtide-vs-amycretin Zenagamtide vs Cagrilintide: https://peptrackerpro.com/compare/zenagamtide-vs-cagrilintide Zenagamtide vs CagriSema: https://peptrackerpro.com/compare/zenagamtide-vs-cagrisema Zenagamtide vs Semaglutide: https://peptrackerpro.com/compare/zenagamtide-vs-semaglutide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Novo Nordisk — CagriSema and zenagamtide data at ADA 2026 Scientific Sessions. June 5, 2026 PubMed (https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html) 2. [2] Zenagamtide (Amycretin): 14.5% Weight Loss, Phase 3 (2026) — Remy Peptides PubMed (https://remypeptides.com/research/zenagamtide-amycretin-glp1-amylin) 3. [3] Novo Nordisk Pipeline Showdown — CagriSema and Zenagamtide at ADA 2026 PubMed (https://www.ad-hoc-news.de/boerse/news/ueberblick/novo-nordisk-juggles-promising-pill-rollout-and-sobering-stock-metrics-in/69480011) ### Keep researching in the app - Log Zenagamtide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=zenagamtide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Zenagamtide", "description": "A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026.", "url": "https://peptrackerpro.com/peptides/zenagamtide", "lastReviewed": "2026-06-05", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Zenagamtide", "item": "https://peptrackerpro.com/peptides/zenagamtide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Researchers following the obesity pipeline beyond approved GLP-1 therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Zenagamtide is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026." } }, { "@type": "Question", "name": "Clinicians interested in next-generation amylin-GLP-1 combination approaches?", "acceptedAnswer": { "@type": "Answer", "text": "Zenagamtide is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026." } }, { "@type": "Question", "name": "Those tracking Novo Nordisk's post-CagriSema pipeline strategy?", "acceptedAnswer": { "@type": "Answer", "text": "Zenagamtide is a research peptide studied in preclinical models. A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026." } } ] } ] ```